Status:

RECRUITING

Mindfulness App Training for Cardiovascular Health

Lead Sponsor:

University of Pittsburgh

Collaborating Sponsors:

National Heart, Lung, and Blood Institute (NHLBI)

Conditions:

Cardiovascular Diseases

Mindfulness

Eligibility:

All Genders

45+ years

Phase:

NA

Brief Summary

This study will investigate the feasibility and effects of a smartphone-based mindfulness training program vs. usual care in a sample of stressed midlife and older adults at risk for cardiovascular di...

Detailed Description

This study is aimed at assessing the feasibility and effects of a smartphone-based mindfulness training program vs. usual care. The objective is to determine the program's effectiveness in reducing st...

Eligibility Criteria

Inclusion

  • Age 45 years or older
  • Fluent in English and proficient in reading English
  • Living in the Pittsburgh area for the next 5 months and available for study visits and activities during this period
  • High perceived stress (greater than or equal to 14 on the 10-item Perceived Stress Scale)
  • Diagnosed with hypertension by medical provider and, if medicated, blood pressure below 150/100, or if unmedicated, clinic blood pressure reading greater than or equal to 125/75 and less than 150/100
  • Moderate-to-high cardiovascular disease risk, as indicated by hypertension and at least 1 of the following:
  • Diagnosed with diabetes by medical provider
  • Diagnosed with high cholesterol by medical provider
  • Current smoker by self-report (smoking or vaping every day or nearly every day)
  • Body Mass Index ≥30
  • Android or iOS smartphone that meets study requirements
  • Participant otherwise able to meet study requirements

Exclusion

  • Clinical or symptomatic atherosclerotic disease, including ischemic heart disease, heart failure, angina, stroke, or atrial fibrillation
  • Two or more "night shift" episodes in the past month
  • Pregnancy
  • Typical alcohol consumption ≥15 drinks per week
  • Marijuana or hashish use \>9 of the past 30 days
  • Use of other controlled substances (e.g., cocaine, crack, heroin, meth, ecstasy) in the past 30 days
  • Current moderate-to-severe depressive symptoms (score ≥15 on PHQ-9)
  • Suicidal ideation (PHQ-9 item 9 score \>0)
  • Positive PTSD screen (traumatic event(s) endorsed and total score ≥3 on Primary Care PTSD screen for DSM-5)
  • Positive Bipolar Disorder screen (≥7 yes responses to item 1, yes to item 2, and moderate or serious on item 3 of Mood Disorder Questionnaire)
  • Positive screen for psychosis (≥1 on Two-Item Screen for Early Psychosis)
  • Regular systematic mind-body practice (e.g., yoga or meditation \>2 times/week)
  • Current participation in another clinical trial or in a study that uses smartphone software

Key Trial Info

Start Date :

February 6 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 30 2026

Estimated Enrollment :

105 Patients enrolled

Trial Details

Trial ID

NCT06152185

Start Date

February 6 2024

End Date

April 30 2026

Last Update

July 18 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Pittsburgh

Pittsburgh, Pennsylvania, United States, 15213